MetLife Investment Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

MetLife Investment Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-30,890	Closed	-$549K	–	2633
2018 Q3	$549K	Hold	30,890	–	–	0.01%	1479
2018 Q2	$426K	Buy	+30,890	New	+$367K	0.01%	1503

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

MetLife Investment Management's ECYT Position: Q4 2018 in Review

MetLife Investment Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 30,890 shares — an estimated $549K sold.

MetLife Investment Management first reported a position in ECYT in Q2 2018 and held it in 2 quarters. The position peaked at $549K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

MetLife Investment Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
MetLife Investment Management sold 30,890 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $549K.
MetLife Investment Management first reported a position in Endocyte, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
MetLife Investment Management's Endocyte, Inc. Common Stock position peaked at $549K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on MetLife Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.